What the company does
i-SENS makes medical sensors and measuring instruments that let people check their own blood-glucose levels at home, as well as diagnostic equipment used by hospitals at the point of care, meaning tests done on-site rather than sent to a lab.
Its products are used by both individual patients managing diabetes and by healthcare professionals in clinical settings. The company's two core business lines are its consumer blood-glucose monitoring segment and its point-of-care testing segment, listed on KOSDAQ, South Korea's tech-focused smaller-company board.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$192.1M
- FY2024US$211M
- FY2025US$228.6M
Operating profit
- FY2023US$7.9M
- FY2024US$1.9M
- FY2025US$5.7M
Net income
- FY2023US$2.5M
- FY2024−US$1.4M
- FY2025−US$11.6M
Key ratios (FY2025)
Filings
All disclosures · English when translatedPrice charts coming soon
Interactive price history isn't here yet. Would you use it?